Subjects with Advanced or Metastatic Small Cell Lung CancerStatus: open
A Randomized, Open-Label, Multicenter, Phase 3 Study of Rovalpituzumab Tesirine Compared with Topotecan for Subjects with Advanced or Metastatic DLL3high Small Cell Lung Cancer (SCLC) who have First Disease Progression During or Following Front-Line Pl
Treatment for Lung Cancer
To assess if treatment with rovalpituzumab tesirine improves objective response rate (ORR) and overall survival (OS) compared to topotecan in subjects with advanced or metastatic DLL3high SCLC who have first disease progression during or following front-line platinum based chemotherapy.Therefore, exploration of new therapies in second line SCLC is warranted, with the goals of extending disease control and improving overall survival.
SponsorsThis trial is sponsored by AbbVie.
Interested in Clinical Trial?
Providers Associated With This Trial
- Moh'd Khushman, M.D.Medical OncologistAssistant Professor of Interdisciplinary Clinical Oncology
- Daniel G. Cameron, M.D.Medical OncologistSenior Staff Medical Oncologist, Medical Oncology Service; Associate Professor of Interdisciplinary Clinical Oncology